melanoma will have micrometastases to their kidneys, clinically apparent kidney metastasis is rare. Few cases have been reported that are related to the actual kidney disease burden or direct effect of treatment on the disease. Reports describing metastatic melanoma with kidney involvement vary. For example, Howse et al. 3 and Faria et al. 4 described cases of nephrotic syndrome secondary to intraglomerular capillary involvement and disruption of the basement membrane and immune-complex deposition, respectively. Ozluk et al. 5 described a case of kidney injury and crescentic lesions, while Gambichler et al. 6 described a case of melanuria secondary to melanin disposition in the tubules, interstitium, and glomerular capillaries. Tumor lysis syndrome (TLS), either spontaneous or secondary to therapy, is rarely reported in metastatic melanoma and no cases have previously discussed TLS in the setting of intraglomerular metastasis (IGM). Here, we present a unique case of AKI secondary to extensive multifocal tubulointerstitial and IGM of malignant melanoma and the development of TLS.
Case report
A 45-year-old male with an established diagnosis of metastatic malignant melanoma and baseline normal kidney function presented to the emergency department (ED) for abdominal discomfort, anorexia, nausea, and shortness of breath for 1 week. He was on a clinical trial of an immune check-point inhibitor, Pembrolizumab (anti-PD1 antibody) and azacitidine (clinicaltrail.gov identifier; NCT02816021). The physical exam was notable for a heart rate in the 120 s, dry mucous membranes, and tense abdominal ascites-no other stigmata of liver disease was present. On admission, his lab results revealed evidence of AKI with serum creatinine (SCr) value of 2.25 mg/dL (SCr values 6 days prior to admission was 1.1 mg/dL). Urinalysis was notable for 25 white blood cell (WBC) and 62 red blood cell (RBC) per high-power field, and microalbuminuria (urine protein to creatinine ratio: 0.12). Urine microscopy revealed numerous hyaline casts, and no granular or cellular casts were observed. Liver enzymes, international normalized ratio, total bilirubin, and platelets were within normal range. Albumin was 3 g/dL. A computer tomography (CT) scan obtained in the ED showed disease progression to the liver, lungs, lymph nodes, bones, adrenal glands, and peritoneum with new onset ascites. There was no obvious evidence of kidney involvement or hydronephrosis on imaging. The initial differential diagnosis for AKI included: pre-renal AKI due to decreased effective arterial volume secondary from poor oral intake, abdominal compartment syndrome, AIN secondary to pembrolizumab use, or hepatorenal syndrome (HRS).
Despite repeated therapeutic paracentesis and volume expansion with albumin, the patient's kidney function continued to deteriorate. Subsequently, a trial of low-dose prednisone (1 mg/kg) was initiated empirically to treat possible AIN from pembrolizumab. The clinical suspicious for HRS was low as the patient had an active urine sediment with RBCs, and his liver synthetic function and enzymes were within normal range. Over the next 5 days, the SCr continued to rise (plateaued at 4.1 mg/dL), and the patient became oliguric. A diagnostic ultrasound-guided kidney biopsy was performed which revealed marked metastatic melanoma cell infiltration characterized by multifocal tubulointerstitial and intraglomerular metastases (Figures 1-3) . A mild tubular injury pattern was also observed, but there was no evidence of nephritis. Urine cytology was also positive for SOX-10, a nuclear transcription factor that has a key role in melanocytic cell differentiation and is considered to be a highly sensitive and specific diagnostic marker for melanoma in both primary and metastatic lesions. 7 Paclitaxel and ipilimumab (clinicaltrail.gov identifier; NCT01827111) therapy was then attempted in hopes of targeting the metastases and improving kidney function. Unfortunately, within 24 h of paclitaxel administration, the patient developed what appeared to be the beginning of TLS; the serum potassium increased from 4.0 to 6.2 mEq/L, lactate dehydrogenase (LDH) from 2608 to 7650 mg/dL, uric acid from 11 to 18.5 mg/dL, and phosphorus from 6 to 10.5 mg/dL ( Figure 4 ). He became altered, hemodynamically unstable, and transferred to the critical care unit, where he was intubated and ventilated. Rasburicase (6 mg) was administered and continuous renal replacement therapy (CRRT) was initiated.
Over the ensuing 4 days, the patient developed progressive pancytopenia (hemoglobin 7.9 g/dL, white cell count and platelet of 0.4 and 80 thousand cells per microliter, respectively), which was attributed to chemotherapyinduced myelosuppression with no evidence of splenomegaly or hemolysis. The patient's condition did not improve despite continued supportive care. Placement of a palliative intraperitoneal catheter was performed for refractory ascites and despite aggressive supportive measures including renal replacement therapy, the patient eventually succumbed to his disease.
Microscopic findings
Melanoma cells were present as both interstitial nodules that displace kidney parenchyma and within occasional glomerular capillaries (Figures 1 and 2 ), which is consistent with hematogenous and potentially microembolic seeding. No significant tubulointerstitial inflammation was observed. Widely scattered, isolated CD68-positive macrophages were present within the interstitium and occasionally within the tumor nodules. Widely scattered, mainly isolated, and slightly more numerous CD3-positive T-cells were present primarily within the cortical interstitium, but not within the tumor nodule. There was a focal tubular epithelial injury which may have resulted from melanoma tubular or vascular occlusion.
Discussion
Nearly half of the patients with metastatic melanoma have kidney metastasis on autopsy; however, it is rarely clinically detected. 8 The majority of these metastases are small cortical nodules generally less than 1 cm in size. The few malignant melanoma cases that specifically describe complications of metastasis to the kidney include: nephrotic syndrome secondary to melanoma cell infiltration to intraglomerular capillaries with glomerular basement disruption, nephrotic syndrome with AKI with evidence of melanoma-antibody deposition in glomerular and tubular basement membranes, AKI with intraglomerular tumor deposition, and AKI with melanuria from melanin deposition to the tubules, interstitium, and glomerular capillaries. 3, 4, 5, 6, 9 Kidney manifestations associated with metastatic melanoma are summarized in Tables 1 and 2 .
Glomerular involvement can occur in the setting of disseminated malignancies of various types with the most Olson et al., 9 Faria et al., 4 Ozluk et al. 5 
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Gambichler et al. 6 (Continued) common kidney finding of microscopic hematuria and proteinuria with rare case reports of significant kidney impairment. 21, 22 Ozluk et al. 5 described a case of a 67-yearold woman presenting with AKI, hematuria, sub-nephrotic range proteinuria, and biopsy-proven melanoma demonstrating diffuse glomerular involvement. The similarities with our case include the chest wall being the primary site of melanoma, the presence of hematuria and proteinuria, and presence of intra-and extracapillary metastasis. The essential differences being Ozluk's et al. patient had diffuse glomerular involvement, whereas our patient only had focal glomerular involvement but also focal tubular epithelial injury. We speculate that the tubular injury noted on pathology might be related to obstruction or vascular occlusion from the melanoma if generalized throughout both kidneys, and this may have been the cause for the patient's rapid decline in kidney function, whereas the focal glomerular metastasis contributed to a lesser degree to the patient's kidney injury. Although the mechanism leading to IGM remains unclear, it has been suggested that proliferation of tumor cells within the capillary lumina followed by tumor cell interposition in the glomerular basement membrane (GBM) results in the extravasation of tumor cells into the glomeruli. 5 TLS is considered a very rare but serious complication of malignant metastatic melanoma. Several case reports have reported in the past few years. Most of these reports discuss the association of TLS in patients with metastatic melanoma secondary to variable etiologies (spontaneous, corticosteroids, chemotherapy including paclitaxel, check-point inhibitors, and radiation therapy). We have summarized the characteristics of these 11 published cases with TLS in Table 3 . Interestingly all cases had liver metastasis, and there was a wide age distribution among the patients who developed TLS (36-76 years of age). The majority of the reported cases were men and about half of the cases required renal replacement therapy. All these patients expired after developing TLS, even the patients who had renal recovery (which was reported in three cases). Our patient had bulky metastatic disease, kidney impairment, and had received a short 5-day course of prednisone followed by paclitaxel 24 h prior to having further decline of his kidney function. His clinical picture and lab results demonstrating an increase in LHD, phosphorus, potassium, and uric acid level is suggestive of tumor lysis syndrome based on Cairo-Bishop criteria. 23 An association between TLS with check-point inhibitors and paclitaxel has been reported previously-all cases developed within 7 days of receiving the therapy. 25, [27] [28] [29] In the current case, our patient was off pembrolizumab for over 4 weeks, when the development of TLS became apparent. This might suggest that paclitaxel was the triggering element, but a multifactorial etiology due to concomitant prednisone use or spontaneous lysis cannot be excluded. TLS induced by paclitaxel use was reported in patients with breast, ovarian, and endometrial cancer. [27] [28] [29] This is the first reported case of paclitaxel-related TLS in the setting of malignant metastatic melanoma.
Conclusion
AKI secondary to possible focal tubular injury due to vascular occlusion or tubular obstruction by melanoma and intraglomerular metastasis is a rare clinical entity that can develop in patients with advanced metastatic disease. Furthermore, clinical outcomes can be adversely affected by TLS during immunotherapy and/or chemotherapy. Patients with a large tumor burden, liver metastasis, and evidence of kidney injury might benefit from TLS prophylaxis prior to initiating chemo-or immunotherapy.
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